Remicade News and Research

RSS

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

New drug shows promise in treating Crohn's disease

According to two new studies the drug certolizumab has proved to be a safe and effective treatment for moderate-to-severe Crohn's disease.

21 Jul 2007

Leading-edge treatment for Crohn's disease at Pediatric Infusion Center

Seventeen-year-old Eliot Drieband explains what it's like to have Crohn's disease - a type of inflammatory bowel disease - in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for teens and being a peer counselor for other kids facing chronic, life-altering illnesses.

9 Jul 2007

Remicade helps those with ankylosing spondylitis

Data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE, (infliximab) over two years experienced significant improvement in spinal mobility.

19 Jun 2007

Long-term ulcerative colitis study shows Remicade responders maintained improvement

Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

24 May 2007

Adalimumab shows potential for Crohn's disease

A study led by Mayo Clinic found that adalimumab (HUMIRA) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE) therapy.

2 May 2007

New Crohn's disease treatment Humira promises to reduce symptoms

The Food and Drug Administration (FDA) in the United States has given it's approval for the use of the drug Humira (adalimumab) to treat adults suffering from Crohn's disease.

28 Feb 2007

FDA approves Humira (adalimumab) for Crohn's disease

The U.S. Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.

27 Feb 2007

Arthritis drugs not as risky as first thought

Researchers now say that two biotech drugs used to treat rheumatoid arthritis, Humira (Abbott Laboratories) and Remicade (Johnson & Johnson), may not raise the risk of cancer and infections as much as was initially feared.

8 Nov 2006

Topical treatment for psoriasis, eliminates need for injections

Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.

17 Oct 2006

Drug infliximab may help ease ulcerative colitis

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.

12 Sep 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

Remicade receives European approval for treatment of psoriatic arthritis

Schering-Plough Corporation today announced that the European Commission has approved the use of Remicade (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.

26 Jul 2006

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Schering-Plough Corporation today announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade (infliximab) to include the treatment of early rheumatoid arthritis (RA) and approved a new indication for psoriatic arthritis (PsA).

23 Mar 2006